Cell therapy manufacturing plant to be built in Devens
The United States Food and Drug Administration (FDA) has approved commercial production at Bristol Meyer Squibb’s (BMS) new cell therapy manufacturing facility.
Located in Devens, this site is an important component of the expanding global cell therapy manufacturing footprint of BMS, and enables the long-term supply of the cell therapies made by the company. The new facility will span 244,000 square feet and it will be the second expansion of BMS on its site in Devens, which covers 89 acres.
BMS has been developing, producing, and testing commercial and clinical medicines for over 10 years. Over 500 new jobs will be created by the facility in Devens, many of which typically require business card printing services, and they demonstrate the growth and leadership of BMS in the dynamic life sciences community of the Boston area. Two research and development facilities are operated by BMS in Cambridge, which will be brought together in one building later this year at Cambridge Crossing.
Executive vice president of Global Product Development and Supply at BMS, Karin Shanahan, said that the latest state-of-the-art technology will be an essential component of the facility in Devens. Shanahan added that top talent from the Boston area who be able to lead the company into its next phase of the development of its cell therapies.
Located in Devens, this site is an important component of the expanding global cell therapy manufacturing footprint of BMS, and enables the long-term supply of the cell therapies made by the company. The new facility will span 244,000 square feet and it will be the second expansion of BMS on its site in Devens, which covers 89 acres.
BMS has been developing, producing, and testing commercial and clinical medicines for over 10 years. Over 500 new jobs will be created by the facility in Devens, many of which typically require business card printing services, and they demonstrate the growth and leadership of BMS in the dynamic life sciences community of the Boston area. Two research and development facilities are operated by BMS in Cambridge, which will be brought together in one building later this year at Cambridge Crossing.
Executive vice president of Global Product Development and Supply at BMS, Karin Shanahan, said that the latest state-of-the-art technology will be an essential component of the facility in Devens. Shanahan added that top talent from the Boston area who be able to lead the company into its next phase of the development of its cell therapies.